Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“One Pfizer” Restructuring Initiative Divides R&D And Sales Operations

Executive Summary

Pfizer's latest corporate restructuring represents a shift away from its recent alignment of research & development and commercialization operations
Advertisement

Related Content

Roche Re-Models Around Disease Areas, Pulls Together R&D And Commercial
Pfizer’s Brandt to retire
Pfizer R&D Emphasizes M&A; Deal Structure, Integration To Be More Flexible
Pfizer Cost-Cutting: Details Are Sketchy, But Sales Force Is On The Table
McKindler? New Pfizer CEO Echoes McKinnell’s Views On Payers, Scale
Bristol Interim CEO Pick Fuels Acquisition Rumors, Complicating Search
Amgen Sizes Up Strategy: Small-Scale Acquisitions, Large-Scale R&D
Welcome To Medicare: Pfizer Sees Part D As Key To Rebirth
Pfizer Streamlines Upper Management; Katen Positioned As Heir Apparent
Pfizer Streamlines Upper Management; Katen Positioned As Heir Apparent
Advertisement
UsernamePublicRestriction

Register

PS047500

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel